Cannabis Rescheduling

DEA Comes Out Swinging in Cannabis Rescheduling Hearing

The government argued in support of currently accepted medical use; anti-rescheduling parties attempted to poke holes in the Schedule III recommendation.

DEA Plans to Call Pain Management Doctor, FDA Official to Testify at Cannabis Reschedule Hearing

The Drug Enforcement Administration filed a prehearing statement summarizing its two proposed witnesses’ testimony.

DEA Judge Sets Cannabis Hearing Schedule, Won’t Consider More Participants

The administrative law judge declined to consider pleas from non-parties to participate in the rescheduling hearing for the proposed Schedule III rule.

Should DEA’s One-Sided Cannabis Rescheduling Hearing Be Reason for Concern?

The government may lack a sufficient administrative record to defend a Schedule III decision in judicial review without any pro-rescheduling participants.

DEA Names 7 Anti-Rescheduling Parties for Cannabis Hearing, Zero Pro Parties

Derek C. Julius will be the DEA’s chief administrative law judge to oversee the hearing of a proposed rule to reclassify cannabis as a Schedule III drug.

Feds Haven’t Provided ‘Clear Guidance, Feedback’ to Ohio on Cannabis Rescheduling

The state’s Division of Cannabis Control ‘doesn’t have a lot of great answers’ for its dual-licensed operators, the department’s legal counsel says.

Glass House Brands Deconsolidates Dual-Use Business, Applies for Uplisting of Shares to NYSE

The U.S. cannabis company plans to list its subordinate voting shares on the New York Stock Exchange.

Anti-Rescheduling Parties Ask Court to Stay Schedule III Cannabis Order

A national drug screening association and a private pharmaceutical cannabinoid development company argue they’ll suffer irreparable harm.

Trulieve Approved to Uplist on New York Stock Exchange

The company announced its subordinate voting shares are expected to begin trading under the ticker ‘TRLV’ on June 10 on the NYSE.

5 ‘Aggrieved Persons’ Sue Trump, DOJ Over Cannabis Rescheduling Order

A substance abuse recovery clinic, two doctors, a victims’ advocacy organization and a pharmaceutical company claim the order was unlawful.

7 House Democrats Demand IRS, Treasury Provide 280E Cannabis Guidance

The U.S. representatives sent a letter urging ‘clear, timely guidance’ for state-licensed medical businesses following the DOJ’s rescheduling order.

ATACH Assembles Legal Team to Defend Schedule III, Defeat Prohibitionist Opponents

The American Trade Association for Cannabis and Hemp filed a formal notice to participate in the DEA hearing and retained Shane Pennington of Blank Rome.

Page 1 of 19

Next Page